首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1889196

全球組織工程和再生醫學市場：預測（至2032年）－按產品、材料類型、治療方法、服務模式、應用、最終用戶和地區進行分析

Tissue Engineering and Regeneration Market Forecasts to 2032 - Global Analysis By Product, Material Type, Therapy Approaches, Service Models, Application, End User and By Geography

出版日期: 2025年12月12日 | 出版商:

Stratistics Market Research Consulting | 英文 | 商品交期: 2-3個工作天內

價格

簡介目錄圖表

根據 Stratistics MRC 的數據，預計到 2025 年，全球組織工程和再生醫學市場規模將達到 399.4 億美元，到 2032 年將達到 1,333.9 億美元，預測期內複合年成長率為 18.8%。

組織工程和再生醫學是指利用功能性生物材料修復、替代和改善受損組織和器官的功能。該領域結合了生物材料、治療性細胞和訊號分子，以引導自然再生並恢復組織結構和功能。它融合了工程和生物學，專注於設計支架、支持細胞活性和促進組織修復。其應用範圍廣泛，涵蓋創傷護理、骨骼和軟骨修復、牙齒修復、心臟組織再生和器官重組等領域，旨在滿足自然癒合過程無法滿足的醫療需求。

據全球類風濕關節炎網路稱，關節炎影響著全球超過 3.5 億人，預計到 2040 年，約有 7,800 萬美國成年人將患上這種疾病。

慢性病發生率呈上升趨勢

糖尿病、心血管疾病和肌肉骨骼疾病等慢性病的日益增多，顯著推動了對先進組織工程解決方案的需求。這些疾病往往會導致組織損傷和器官衰竭，加速了再生醫學的發展。人口老化進一步加劇了退化性疾病的盛行率，並推動了工程組織的廣泛應用。因此，再生醫學正成為現代醫療保健的關鍵組成部分。日益加重的疾病負擔是推動市場擴張的強勁動力。

複雜且不明確的調控通路

企業往往難以滿足生物材料、工程組織、複合材料產品等多種產品的核准標準。冗長的臨床檢驗流程進一步延緩了商業化。監管的不確定性增加了合規成本，並延遲了創新治療方法的市場准入。為了避免延誤，研發人員必須在文件編制、品質系統和監管諮詢方面投入大量資金。這些挑戰可能會限制產品上市，並抑制更廣泛的市場成長。

發揮3D生物列印的潛力

列印技術的進步使得對細胞定位、支架結構和材料成分的控制更加精準。這些創新促進了用於移植和藥物測試的功能性組織的開發，同時也有助於加快原型製作速度，縮短再生醫學產品的研發週期。 3D生物列印技術的廣泛應用正在推動生物技術公司、研究機構和材料開發商之間的合作。其不斷成長的潛力使其成為市場的重要成長引擎。

報銷政策分散或不完善

許多治療方法屬於新興或未定義類別，導致保險覆蓋範圍難以預測。有限的保險支持阻礙了醫療機構和患者採用再生療法。評估標準的差異也使得生產商難以證明其成本效益。這些挑戰延緩了臨床應用，並阻礙了大規模商業化。如果沒有更健全的報銷機制，市場發展可能會受到限制。

新冠疫情的感染疾病：

疫情初期擾亂了供應鏈，推遲了擇期手術，並影響了對組織工程產品的需求。多家機構的研究被迫暫停，導致創新週期放緩。然而，新冠肺炎疫情凸顯了先進生物材料和再生醫學工具在治療和復健中的重要性。這場危機加速了政府和私人對生物醫學研究的投資。疫情後的復甦重新燃起了人們對利用再生醫學治療慢性疾病的興趣。

預測期內，支架和生物材料領域將佔據最大的市場佔有率。

由於支架和生物材料在組織工程過程中發揮基礎性作用，預計在預測期內，它們將佔據最大的市場佔有率。這些構建模組為細胞黏附和組織形成提供了必要的結構支撐。可生物分解聚合物、水凝膠和生物活性材料的創新正在拓展其應用範圍。它們在研究、臨床試驗和商業性治療中的廣泛應用，正在鞏固該領域的市場地位。對可客製化和生物相容性材料的日益成長的需求，也進一步推動了市場需求。

預測期內，生技公司板塊的複合年成長率將最高。

由於再生醫學領域研發的快速發展，預計生技公司板塊在預測期內將達到最高成長率。對新型生物材料、細胞療法和工程組織的重點關注正在推動創新加速。許多公司正與醫院和學術機構建立策略合作夥伴關係，以擴大突破性成果。不斷成長的創業投資資金正在助力公司拓展臨床試驗和商業化進程。這些公司也積極採用3D生物列印和幹細胞工程等最尖端科技。

佔比最大的地區：

預計北美將在預測期內佔據最大的市場佔有率，這主要得益於其強大的醫療保健基礎設施和較高的技術普及率。該地區受益於充足的研究經費和頂尖大學的積極參與。支持再生醫學的法規結構進一步促進了產品開發。美國和加拿大慢性病發病率的上升推動了對先進組織治療的需求。領先生物技術公司的存在增強了創新和商業化生態系統。

年複合成長率最高的地區：

預計亞太地區在預測期內將實現最高的複合年成長率，這主要得益於醫療保健投資的成長和生物醫學研究的進步。中國、日本和印度等國家正迅速採用再生醫學技術。政府為促進生物技術和組織工程而採取的措施正在加速市場滲透。慢性病和退化性疾病患者數量的增加，催生了對先進治療方法的強勁需求。全球企業與區域機構之間日益密切的合作也推動了相關領域的發展。

免費客製化服務：

訂閱本報告的用戶可從以下免費自訂選項中選擇一項：

公司簡介
- 對最多三家其他公司進行全面分析
- 對主要企業進行SWOT分析（最多3家公司）
區域分類
- 根據客戶興趣對主要國家進行市場估算、預測和複合年成長率分析（註：基於可行性檢查）
競爭基準化分析
- 基於產品系列、地域覆蓋和策略聯盟對主要企業基準化分析

北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 德國
- 英國
- 義大利
- 法國
- 西班牙
- 其他歐洲
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 紐西蘭
- 韓國
- 亞太其他地區
南美洲
- 阿根廷
- 巴西
- 智利
- 其他南美國家
中東和非洲
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 卡達
- 南非
- 其他中東和非洲地區

第12章：主要趨勢

合約、商業夥伴關係和合資企業
企業合併（M&A）
新產品上市
業務拓展
其他關鍵策略

第13章：企業概況

Organogenesis
Mesoblast Limited
Stryker Corporation
CollPlant Biotechnologies
Integra LifeSciences
Baxter International
Medtronic plc
Merck KGaA
Zimmer Biomet
Corning Incorporated
BICO
Lonza Group
Organovo Holdings
3M Company
Tissue Regenix

簡介目錄圖表

Product Code: SMRC32656

According to Stratistics MRC, the Global Tissue Engineering and Regeneration Market is accounted for $39.94 billion in 2025 and is expected to reach $133.39 billion by 2032 growing at a CAGR of 18.8% during the forecast period. Tissue engineering and regeneration refer to creating functional biological materials that help repair, replace, or enhance injured tissues and organs. The discipline merges biomaterials, therapeutic cells, and signaling molecules to guide natural regeneration and rebuild structure and function. Using engineering and biological science, it focuses on designing scaffolds, supporting cell activity, and driving tissue restoration. Its use extends across wound care, bone and cartilage repair, dental restoration, heart tissue regeneration, and organ reconstruction, addressing medical needs unmet by natural healing processes.

According to the Global RA Network, arthritis affects over 350 million people worldwide, and projections suggest that by 2040, approximately 78 million U.S. adults will suffer from the condition.

Market Dynamics:

Driver:

Rising prevalence of chronic diseases

The rising incidence of chronic illnesses such as diabetes, cardiovascular disorders, and musculoskeletal conditions is significantly increasing the need for advanced tissue engineering solutions. These diseases often lead to tissue damage or organ failure, intensifying demand for regenerative therapies. Growing aging populations further amplify the prevalence of degenerative disorders, supporting wider adoption of engineered tissues. As a result, regenerative medicine is becoming a central component of modern healthcare pathways. This accelerating disease burden serves as a strong catalyst for market expansion.

Restraint:

Complex and unclear regulatory pathways

Companies often struggle to meet diverse approval standards for biomaterials, engineered tissues, and combination products. Lengthy clinical validation processes further slow commercialization efforts. Regulatory ambiguity increases compliance costs and delays market entry for innovative therapies. Developers must invest heavily in documentation, quality systems, and regulatory consultations to avoid setbacks. These challenges can restrict product launches and limit broader market growth.

Opportunity:

Harnessing the potential of 3D bioprinting

Advances in printing technologies allow improved control over cell placement, scaffold architecture, and material composition. This innovation enhances the development of functional tissues for transplantation and drug testing. The technique also supports faster prototyping, reducing development timelines for regenerative products. As 3D bioprinting becomes more accessible, it is driving collaborations between biotech firms, research institutes, and material developers. Its expanding potential positions it as a major growth engine for the market.

Threat:

Fragmented or inadequate reimbursement policies

Many therapies fall under emerging or undefined categories, making coverage decisions unpredictable. Limited insurance support discourages both clinics and patients from choosing regenerative treatments. Manufacturers face difficulties demonstrating cost-effectiveness due to varying evaluation criteria. These gaps slow down clinical uptake and hinder large-scale commercialization. Without stronger reimbursement structures, market progression may remain constrained.

Covid-19 Impact:

The pandemic initially disrupted supply chains and delayed elective procedures, affecting demand for tissue-engineered products. Research activities in several institutions were temporarily halted, slowing innovation cycles. However, Covid-19 highlighted the importance of advanced biomaterials and regenerative tools for healing and recovery. The crisis accelerated government and private investments in biomedical research. Post-pandemic rebuilding has driven renewed interest in regenerative medicine for chronic condition management.

The scaffolds & biomaterials segment is expected to be the largest during the forecast period

The scaffolds & biomaterials segment is expected to account for the largest market share during the forecast period, due to its foundational role in tissue engineering processes. These components provide essential structural support for cell attachment and tissue formation. Growing innovation in biodegradable polymers, hydrogels, and bioactive materials is expanding their application range. Their high usage in research, clinical studies, and commercial therapies strengthens the segment's market position. Increasing preference for customizable and biocompatible materials further drives demand.

The biotechnology companies segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the biotechnology companies segment is predicted to witness the highest growth rate, as they rapidly advance R&D in regenerative therapies. Their strong focus on novel biomaterials, cell therapies, and engineered tissues fuels accelerated innovation. Many firms are entering strategic partnerships with hospitals and academic institutions to scale breakthroughs. Increased venture funding is enabling expansion into clinical trials and commercialization pathways. These companies are also adopting cutting-edge technologies such as 3D bioprinting and stem cell engineering.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to its strong healthcare infrastructure and high technological adoption. The region benefits from extensive research funding and active participation from leading universities. Regulatory frameworks supporting regenerative medicine further encourage product development. Rising chronic disease cases in the U.S. and Canada increase the need for advanced tissue therapies. Presence of major biotech companies strengthens the ecosystem for innovation and commercialization.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by growing healthcare investments and expanding biomedical research. Countries such as China, Japan, and India are rapidly adopting regenerative technologies. Government initiatives promoting biotechnology and tissue engineering are accelerating market penetration. Rising patient populations with chronic and degenerative conditions create strong demand for advanced therapies. Increasing collaborations between global players and regional institutes boost developmental activities.

Key players in the market

Some of the key players in Tissue Engineering and Regeneration Market include Organogen, Mesoblast, Stryker Co, CollPlant B, Integra Lif, Baxter Int, Medtronic, Merck KGa, Zimmer Bi, Corning In, BICO, Lonza Gro, Organovo, 3M Comp, and Tissue Re.

Key Developments:

In October 2025, Merck has entered into a partnership with Promega Corporation, a global life science solutions and service leader based in Madison, Wisconsin in the US, to co-develop novel technologies that advance drug screening and discovery. The agreement unites Merck's strength in organoids and synthetic chemistry with Promega's market leading assay and reporter technologies. Together, the companies aim to develop assays capable of tracking cellular activity in real time using an innovative reporter system within three-dimensional (3D) cell cultures.

In December 2024, 3M and US Conec Ltd. announced a strategic licensing agreement for 3M(TM) Expanded Beam Optical Interconnect technology, a solution to meet the performance and scalability needs of next-generation data centers and advanced network architectures. The collaboration combines advanced optical technology from 3M with US Conec's expertise in high-density connectivity systems, expanded beam optics, and precision manufacturing to help deliver innovative solutions tailored to the evolving demands of modern networks.

Products Covered:

Scaffolds & Biomaterials
Cells & Cell Banks
Bio-inks & Consumables
Bioreactors & Culture Systems
Diagnostics & Monitoring Tools
CDMO / Contract Services
Other Products

Material Types Covered:

Natural Polymers
Synthetic Polymers
Ceramics & Bioactive Glasses
Composites
Hydrogels / ECM Mimetics

Therapy Approaches Covered:

Cell Therapy-Based
Scaffold-Guided
Acellular Biologics / Secretome
Combination Products
Synthetic Tissue Substitutes

Service Models Covered:

Off-the-Shelf Product
Personalized/autologous Therapies
Contract Development & Manufacturing
Research Services & Licensing

Applications Covered:

Orthopedic
Cardiovascular
Dermatology & Wound Healing
Neural
Ophthalmology
Urology & Nephrology
Gastrointestinal & Hepatic
Dental & Maxillofacial
ENT & Reconstructive

End Users Covered:

Hospitals & Surgical Centers
Research Institutes & Academia
Biotech & Pharma Companies
CROs / CDMOs
Diagnostic Labs
Other End Users

Regions Covered:

North America
- US
- Canada
- Mexico
Europe
- Germany
- UK
- Italy
- France
- Spain
- Rest of Europe
Asia Pacific
- Japan
- China
- India
- Australia
- New Zealand
- South Korea
- Rest of Asia Pacific
South America
- Argentina
- Brazil
- Chile
- Rest of South America
Middle East & Africa
- Saudi Arabia
- UAE
- Qatar
- South Africa
- Rest of Middle East & Africa

What our report offers:

Market share assessments for the regional and country-level segments
Strategic recommendations for the new entrants
Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
Strategic recommendations in key business segments based on the market estimations
Competitive landscaping mapping the key common trends
Company profiling with detailed strategies, financials, and recent developments
Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

Company Profiling
- Comprehensive profiling of additional market players (up to 3)
- SWOT Analysis of key players (up to 3)
Regional Segmentation
- Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
Competitive Benchmarking
- Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

1 Executive Summary

2 Preface

2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
- 2.4.1 Data Mining
- 2.4.2 Data Analysis
- 2.4.3 Data Validation
- 2.4.4 Research Approach
2.5 Research Sources
- 2.5.1 Primary Research Sources
- 2.5.2 Secondary Research Sources
- 2.5.3 Assumptions

3 Market Trend Analysis

3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Product Analysis
3.7 Application Analysis
3.8 End User Analysis
3.9 Emerging Markets
3.10 Impact of Covid-19

4 Porters Five Force Analysis

4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Global Tissue Engineering and Regeneration Market, By Product

5.1 Introduction
5.2 Scaffolds & Biomaterials
5.3 Cells & Cell Banks
5.4 Bio-inks & Consumables
5.5 Bioreactors & Culture Systems
5.6 Diagnostics & Monitoring Tools
5.7 CDMO / Contract Services
5.8 Other Products

6 Global Tissue Engineering and Regeneration Market, By Material Type

6.1 Introduction
6.2 Natural Polymers
6.3 Synthetic Polymers
6.4 Ceramics & Bioactive Glasses
6.5 Composites
6.6 Hydrogels / ECM Mimetics

7 Global Tissue Engineering and Regeneration Market, By Therapy Approaches

7.1 Introduction
7.2 Cell Therapy-Based
7.3 Scaffold-Guided
7.4 Acellular Biologics / Secretome
7.5 Combination Products
7.6 Synthetic Tissue Substitutes

8 Global Tissue Engineering and Regeneration Market, By Service Models

8.1 Introduction
8.2 Off-the-Shelf Product
8.3 Personalized/autologous Therapies
8.4 Contract Development & Manufacturing
8.5 Research Services & Licensing

9 Global Tissue Engineering and Regeneration Market, By Application

9.1 Introduction
9.2 Orthopedic
9.3 Cardiovascular
9.4 Dermatology & Wound Healing
9.5 Neural
9.6 Ophthalmology
9.7 Urology & Nephrology
9.8 Gastrointestinal & Hepatic
9.9 Dental & Maxillofacial
9.10 ENT & Reconstructive

10 Global Tissue Engineering and Regeneration Market, By End User

10.1 Introduction
10.2 Hospitals & Surgical Centers
10.3 Research Institutes & Academia
10.4 Biotech & Pharma Companies
10.5 CROs / CDMOs
10.6 Diagnostic Labs
10.7 Other End Users

11 Global Tissue Engineering and Regeneration Market, By Geography

11.1 Introduction
11.2 North America
- 11.2.1 US
- 11.2.2 Canada
- 11.2.3 Mexico
11.3 Europe
- 11.3.1 Germany
- 11.3.2 UK
- 11.3.3 Italy
- 11.3.4 France
- 11.3.5 Spain
- 11.3.6 Rest of Europe
11.4 Asia Pacific
- 11.4.1 Japan
- 11.4.2 China
- 11.4.3 India
- 11.4.4 Australia
- 11.4.5 New Zealand
- 11.4.6 South Korea
- 11.4.7 Rest of Asia Pacific
11.5 South America
- 11.5.1 Argentina
- 11.5.2 Brazil
- 11.5.3 Chile
- 11.5.4 Rest of South America
11.6 Middle East & Africa
- 11.6.1 Saudi Arabia
- 11.6.2 UAE
- 11.6.3 Qatar
- 11.6.4 South Africa
- 11.6.5 Rest of Middle East & Africa

12 Key Developments

12.1 Agreements, Partnerships, Collaborations and Joint Ventures
12.2 Acquisitions & Mergers
12.3 New Product Launch
12.4 Expansions
12.5 Other Key Strategies

13 Company Profiling

13.1 Organogenesis
13.2 Mesoblast Limited
13.3 Stryker Corporation
13.4 CollPlant Biotechnologies
13.5 Integra LifeSciences
13.6 Baxter International
13.7 Medtronic plc
13.8 Merck KGaA
13.9 Zimmer Biomet
13.10 Corning Incorporated
13.11 BICO
13.12 Lonza Group
13.13 Organovo Holdings
13.14 3M Company
13.15 Tissue Regenix

簡介目錄圖表

List of Tables

Table 1 Global Tissue Engineering and Regeneration Market Outlook, By Region (2024-2032) ($MN)
Table 2 Global Tissue Engineering and Regeneration Market Outlook, By Product (2024-2032) ($MN)
Table 3 Global Tissue Engineering and Regeneration Market Outlook, By Scaffolds & Biomaterials (2024-2032) ($MN)
Table 4 Global Tissue Engineering and Regeneration Market Outlook, By Cells & Cell Banks (2024-2032) ($MN)
Table 5 Global Tissue Engineering and Regeneration Market Outlook, By Bio-inks & Consumables (2024-2032) ($MN)
Table 6 Global Tissue Engineering and Regeneration Market Outlook, By Bioreactors & Culture Systems (2024-2032) ($MN)
Table 7 Global Tissue Engineering and Regeneration Market Outlook, By Diagnostics & Monitoring Tools (2024-2032) ($MN)
Table 8 Global Tissue Engineering and Regeneration Market Outlook, By CDMO / Contract Services (2024-2032) ($MN)
Table 9 Global Tissue Engineering and Regeneration Market Outlook, By Other Products (2024-2032) ($MN)
Table 10 Global Tissue Engineering and Regeneration Market Outlook, By Material Type (2024-2032) ($MN)
Table 11 Global Tissue Engineering and Regeneration Market Outlook, By Natural Polymers (2024-2032) ($MN)
Table 12 Global Tissue Engineering and Regeneration Market Outlook, By Synthetic Polymers (2024-2032) ($MN)
Table 13 Global Tissue Engineering and Regeneration Market Outlook, By Ceramics & Bioactive Glasses (2024-2032) ($MN)
Table 14 Global Tissue Engineering and Regeneration Market Outlook, By Composites (2024-2032) ($MN)
Table 15 Global Tissue Engineering and Regeneration Market Outlook, By Hydrogels / ECM Mimetics (2024-2032) ($MN)
Table 16 Global Tissue Engineering and Regeneration Market Outlook, By Therapy Approaches (2024-2032) ($MN)
Table 17 Global Tissue Engineering and Regeneration Market Outlook, By Cell Therapy-Based (2024-2032) ($MN)
Table 18 Global Tissue Engineering and Regeneration Market Outlook, By Scaffold-Guided (2024-2032) ($MN)
Table 19 Global Tissue Engineering and Regeneration Market Outlook, By Acellular Biologics / Secretome (2024-2032) ($MN)
Table 20 Global Tissue Engineering and Regeneration Market Outlook, By Combination Products (2024-2032) ($MN)
Table 21 Global Tissue Engineering and Regeneration Market Outlook, By Synthetic Tissue Substitutes (2024-2032) ($MN)
Table 22 Global Tissue Engineering and Regeneration Market Outlook, By Service Models (2024-2032) ($MN)
Table 23 Global Tissue Engineering and Regeneration Market Outlook, By Off-the-Shelf Product (2024-2032) ($MN)
Table 24 Global Tissue Engineering and Regeneration Market Outlook, By Personalized/autologous Therapies (2024-2032) ($MN)
Table 25 Global Tissue Engineering and Regeneration Market Outlook, By Contract Development & Manufacturing (2024-2032) ($MN)
Table 26 Global Tissue Engineering and Regeneration Market Outlook, By Research Services & Licensing (2024-2032) ($MN)
Table 27 Global Tissue Engineering and Regeneration Market Outlook, By Application (2024-2032) ($MN)
Table 28 Global Tissue Engineering and Regeneration Market Outlook, By Orthopedic (2024-2032) ($MN)
Table 29 Global Tissue Engineering and Regeneration Market Outlook, By Cardiovascular (2024-2032) ($MN)
Table 30 Global Tissue Engineering and Regeneration Market Outlook, By Dermatology & Wound Healing (2024-2032) ($MN)
Table 31 Global Tissue Engineering and Regeneration Market Outlook, By Neural (2024-2032) ($MN)
Table 32 Global Tissue Engineering and Regeneration Market Outlook, By Ophthalmology (2024-2032) ($MN)
Table 33 Global Tissue Engineering and Regeneration Market Outlook, By Urology & Nephrology (2024-2032) ($MN)
Table 34 Global Tissue Engineering and Regeneration Market Outlook, By Gastrointestinal & Hepatic (2024-2032) ($MN)
Table 35 Global Tissue Engineering and Regeneration Market Outlook, By Dental & Maxillofacial (2024-2032) ($MN)
Table 36 Global Tissue Engineering and Regeneration Market Outlook, By ENT & Reconstructive (2024-2032) ($MN)
Table 37 Global Tissue Engineering and Regeneration Market Outlook, By End User (2024-2032) ($MN)
Table 38 Global Tissue Engineering and Regeneration Market Outlook, By Hospitals & Surgical Centers (2024-2032) ($MN)
Table 39 Global Tissue Engineering and Regeneration Market Outlook, By Research Institutes & Academia (2024-2032) ($MN)
Table 40 Global Tissue Engineering and Regeneration Market Outlook, By Biotech & Pharma Companies (2024-2032) ($MN)
Table 41 Global Tissue Engineering and Regeneration Market Outlook, By CROs / CDMOs (2024-2032) ($MN)
Table 42 Global Tissue Engineering and Regeneration Market Outlook, By Diagnostic Labs (2024-2032) ($MN)
Table 43 Global Tissue Engineering and Regeneration Market Outlook, By Other End Users (2024-2032) ($MN)